We live in an increasingly digital world. Even more so following Covid-19.
As our field forces transition to an online/hybrid model, we start to think not just about the disadvantages but the new advantages this brings.
One tempting possibility is the promise of ‘next best action’, using AI to give reps direction and guidance on who to approach and how to approach them.
However, like with all digital implementations, success or failure is dependent on ‘how’ you do it.
Listen to BMS, GSK and Astellas in a discussion with OKRA to discover the future of pharma sales and why, actually, simply going with ‘next best action’ may not be sufficient.
For more information or if you have any questions, please contact Rasim Shah, Director at OKRA on firstname.lastname@example.org